Access to Medicines

More on Hepatitis C

KEI Documents and commentary regarding Hepatitis C Virus (HCV) related issues

Briefing Notes

KEI comments on Tibotec voluntary licenses of a new HIV-AIDS product

Today, Tibotec, a subsidiary of Johnson & Johnson, announced it has signed voluntary licensing agreements with several Indian and South African generic companies to allow generic competition on a new HIV-AIDS treatment, the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278) (rilpivirine hydrochloride), to certain developing countries.

Why is there resistance to prize funds?

I was recently asked the following question:

What is your view on the treatment of prize funds? By all standards it is treated as a radical off the wall proposal when in fact it is market based. Why is there so much resistance?

My response was as follows:

Dec 9, 2009 Wikileaks documents related to the WHO EWG

On December 9, 2009, Wikileaks posted five sensitive documents related to the WHO Expert Working Group (EWG) on R&D Financing:

  • a non-public draft report of the WHO EWG
  • a non-public Comparative Analysis done by the EWG
  • the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Overview of the EWG Comparative Analysis
  • an IFPMA summary slide on the EWG Draft Report
  • Open Letter to the WHO EB from Cecilia López Montaño, EWG member

    The following is a letter sent by Cecilia López Montaño, a member of the WHO Expert Working Group on R&D Financing to the WHO Executive Board:

    Bogotá. Colombia. January 15th 2010

    Dear members of the Executive Board:

    I am Cecilia López Montaño, senator of the Colombian Congress and member of the Expert Working Group on Research and Development Financing of the World Health Organization, in representation of the point of view of developing countries, I assume.

    Can the U.S. realistically honor commitments to fund treatment for AIDS in developing countries without generic products?

    14% (54 votes)
    86% (334 votes)
    Total votes: 388

    KEI Statement on UNITAID Decision to Approve Creation of a Patent Pool for AIDS medicines

    On Monday, December 14, the UNITAID board passed a resolution to establish a Patent Pool for AIDS medicines. The decision caped a dramatic debate on the proposal, which had been before UNITAID since 2006, and had been discussed in other fora since 2002. The following is a statement by KEI on the UNITAID decision, followed by background on the UNITAID patent pool proposal, including a copy of the UNITAID press release.

    Statement of James Love, Director of KEI, on the UNITAID Patent Pool:

    Speech of Mike Foster, UK Minister for International Development at launch of Industry Government Forum on Access to Medicines

    On October 12, 2009, the "Industry Government Forum on Access to Medicines" (IGFAM) was launched. The UK Minister for International Development, MP Mike Foster made a a speech to launch this initiative which is reproduced below.

    Presentations were also made by Pfizer (Ponni Subbiah), GSK (Abbas Hussain), Rajiv Venkayya (Gates Foundation), Prashant Yadav (Massachusetts Institute of Technology) and Suerie Moon (Research Fellow and Doctoral Candidate, Kennedy School of Government, Harvard University).

    Syndicate content